Efficacy of Combination Therapy of Fluvoxamine and Favipiravir versus Favipiravir Monotherapy to Prevent Severe COVID-19 among Mild to Moderate COVID-19 Patients: Open-label Randomized Controlled Trial (EFFaCo Study)
M.D. M.Sc Taweegrit Siripongboonsitti, Mullika Buttakosa B.Sc Gaidganok Sornsamdang, M.D Teerapat Ungtrakul, M.D Kriangkrai Tawinprai, B.Sc Tararin Nimmol, B.Sc Mullika Buttakosa, MD Tanadul Jarrusrojwuttikul, M.D Phumin Silapant, M.D Nithi Mahanonda
doi:10.1016/j.ijid.2023.06.018
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
Bast, Tang, Dahn, Palacio, Increased risk of hospitalisation and death with the delta variant in the USA, Lancet Infect Dis,
doi:10.1016/s1473-3099Bernal, Da Silva, Musungaie, Kovalchuk, None
Bramante, Huling, Tignanelli, Buse, Liebovitz et al., Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2201662Cai, Yang, Liu, Chen, Shu et al., Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering,
doi:10.1016/j.eng.2020.03.007Chen, Huang, Cheng, Wu, Chen et al., Favipiravir versus arbidol for COVID-19: a randomized clinical trial, MedRxiv,
doi:10.1101/2020.03.17Chuah, Chow, Hor, Cheng, Ker et al., Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial, Clin Infect Dis,
doi:10.1093/cid/ciab962Du, Chen, Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, Clinical Pharmacology & Therapeutics,
doi:10.1002/cpt.1844Fung, Liu, The ER stress sensor IRE1 and MAP kinase ERK modulate autophagy induction in cells infected with coronavirus infectious bronchitis virus, Virology,
doi:10.1016/j.virol.2019.05.002Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase,
doi:10.2183/pjab.93.027Guo, Harari, Chernecki, Thorlund, Forrest, Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of Randomized Clinical Trials, Am J Trop Med Hyg,
doi:10.4269/ajtmh.21-1310Hammond, Leister-Tebbe, Gardner, Abreu, Wisemandle, Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2118542Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials, Scientific reports,
doi:10.1038/s41598-021-90551-6Hoertel, Sánchez-Rico, De La Muela, Abellán, Blanco et al., Risk of Death in Individuals Hospitalized for COVID-19 With and Without Psychiatric Disorders: An Observational Multicenter Study in France, Biol Psychiatry Glob Open Sci,
doi:10.1016/j.bpsgos.2021.12.007Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial, Clinical Infectious Diseases,
doi:10.1093/cid/ciaa1176Lee, Vigod, Bortolussi-Courval, Hanula, Boulware et al., Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2022.6269Lenze, Mattar, Zorumski, Stevens, Schweiger et al., Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial, Jama,
doi:10.1001/jama.2020.22760Mccarthy, Naggie, Boulware, Lindsell, Stewart et al., Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial,
doi:10.1101/2022.10.17.22281178Németh, Szûcs, Vitrai, Juhász, Németh et al., Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: A retrospective casecontrol study, Ideggyogy Sz,
doi:10.18071/isz.74.0389Oskotsky, Maric, Tang, Oskotsky, Wong et al., Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2021.33090Reis, Santos Moreira-Silva, Silva, Thabane, Milagres et al., Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob Health,
doi:10.1016/s2214-109x(21)00448-4Reis, Santos, Silva, Silva, Thabane et al., Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial, Ann Intern Med,
doi:10.7326/m22-3305Schlienger, Meier, Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction?, Am J Cardiovasc Drugs,
doi:10.2165/00129784-200303030-00001Seftel, Boulware, Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19, Open Forum Infect Dis,
doi:10.1093/ofid/ofab050Seo, Kim, Bae, Park, Chung et al., Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial, Infect Chemother,
doi:10.3947/ic.2021.0142Shrestha, Budhathoki, Khadka, Shah, Pokharel et al., Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis, Virology journal,
doi:10.1186/s12985-020-01412-zSukhatme, Reiersen, Vayttaden, Sukhatme, Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19, Front Pharmacol,
doi:10.3389/fphar.2021.652688
